Park Min-ji has the first chance to lose five games in a row. Park Min-ji received good news. This is because the hosting of ...

Vietnam Pharmaceutical Corporation (Vinapharm), with the state holding a 65% stake, aims to double its stake in the ...

Vietnam Pharmaceutical Corporation (Vinapharm) aims to double its stake in the Vietnamese arm of France’s pharmaceutical ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to ...

Shilpa Medicare Ltd has entered into settlement agreement with Celltrion, Inc dated 17th April 2025 for an amount of US$ 3.4 ...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

US FDA designates Celltrion’s Yuflyma as an interchangeable biosimilar to Humira: Incheon, South Korea Wednesday, April 16, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that ...

As global markets navigate a tumultuous landscape marked by escalating trade tensions and fluctuating consumer sentiment, the tech sector remains a focal point for investors seeking growth ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...